Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth R Hess

Showing results (11-20 of 217) with videos related to

Pageof 22
Sort By:
BMC Cancer|June 26, 2007
Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomasVictor A Levin, Sandra Ictech, Kenneth R Hess
JAMA Oncology|November 13, 2018
Moving Precision Oncology Forward Amid Myths and MisconceptionsFilip Janku, Kenneth R Hess, Timothy A Yap
Neuro-Oncology|August 19, 2008
Prognostic factors and outcomes in patients with leptomeningeal melanomatosisLaura Harstad, Kenneth R Hess, Morris D Groves
CNS Oncology|January 31, 2018
Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomasVictor A Levin, Sandra E Ictech, Kenneth R Hess
Cancer|October 12, 2004
Adult glioma incidence trends in the United States, 1977-2000Kenneth R Hess, Kristine R Broglio, Melissa L Bondy
Annals of Surgery|November 1, 2002
ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreasDouglas B Evans, Kenneth R Hess, Peter W T Pisters
Breast Cancer Research and Treatment|March 4, 2003
Estrogen receptors and distinct patterns of breast cancer relapseKenneth R Hess, Lajos Pusztai, Aman U Buzdar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2016
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology TrialsYing Yuan, Kenneth R Hess, Susan G Hilsenbeck, et al.
The Lancet. Oncology|August 14, 2018
Sex as a predictor of response to cancer immunotherapyJennifer L McQuade, Carrie R Daniel, Kenneth R Hess, et al.
Neuro-Oncology|March 6, 2014
Implications of bevacizumab discontinuation in adults with recurrent glioblastomaMark D Anderson, Mohamed A Hamza, Kenneth R Hess, et al.
Pageof 22

Showing results (11-20 of 217) with videos related to

Sort By:
Pageof 22
BMC Cancer|June 26, 2007
Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomasVictor A Levin, Sandra Ictech, Kenneth R Hess
JAMA Oncology|November 13, 2018
Moving Precision Oncology Forward Amid Myths and MisconceptionsFilip Janku, Kenneth R Hess, Timothy A Yap
Neuro-Oncology|August 19, 2008
Prognostic factors and outcomes in patients with leptomeningeal melanomatosisLaura Harstad, Kenneth R Hess, Morris D Groves
CNS Oncology|January 31, 2018
Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomasVictor A Levin, Sandra E Ictech, Kenneth R Hess
Cancer|October 12, 2004
Adult glioma incidence trends in the United States, 1977-2000Kenneth R Hess, Kristine R Broglio, Melissa L Bondy
Annals of Surgery|November 1, 2002
ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreasDouglas B Evans, Kenneth R Hess, Peter W T Pisters
Breast Cancer Research and Treatment|March 4, 2003
Estrogen receptors and distinct patterns of breast cancer relapseKenneth R Hess, Lajos Pusztai, Aman U Buzdar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2016
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology TrialsYing Yuan, Kenneth R Hess, Susan G Hilsenbeck, et al.
The Lancet. Oncology|August 14, 2018
Sex as a predictor of response to cancer immunotherapyJennifer L McQuade, Carrie R Daniel, Kenneth R Hess, et al.
Neuro-Oncology|March 6, 2014
Implications of bevacizumab discontinuation in adults with recurrent glioblastomaMark D Anderson, Mohamed A Hamza, Kenneth R Hess, et al.
Pageof 22